Skip to main content

Table 3 Comparison study with mammography and Trx1 level

From: The blood level of thioredoxin 1 as a supporting biomarker in the detection of breast cancer

Variable

BI-RADS

Trx1 (95% CI)

No.

%

Breast cancer patientsa

0

23.22 (19.89 to 26.55)

29

28.2

(n = 103)

1

22.02 (NA)

1

1

2

10.26 (NA)

1

1

3

22.38 (NA)

1

1

4

21.84 (20.14 to 23.53)

52

50.5

5

20.43 (17.87 to 22.99)

19

18.4

6

0(NA)

0

0

Women without cancerb

0

2.53(NA)

1

2.4

(n = 42)

1

6.16(4.49 to 7.82)

32

76.2

2

6.10(2.34 to 9.87)

8

19

3

3.61(NA)

1

2.4

Variable

Confirmed BC patients

Women without cancer

 

Mammography

BI-RADS 4-5

71

0

 

BI-RADS 0-3

32

42

 

Total

103

42

 

Trx1

≥ 11.4 ng/ml

100

5

 

<  11.4 ng/ml

3

37

 

Total

103

42

 

Mammography + Trx1c

Positive

101

0

 

Negative

2

42

 

Total

103

42

 

Variable

Sensitivity(%)

Specificity(%)d

 

Mammography

68.93

100.00

 

Trx1

97.09

88.10

 

Mammography + Trx1

98.06

100.00

 
  1. a BC patients were selected first by their biopsy results, and their matching mammograms were retrieved afterward for analysis. There was 103 out of the 106 participating BC patients
  2. bThe women without cancer was classified according to BI-RADS score. Among the candidates (n = 114), only those whose prior mammograms were archived at CNUH were selected (n = 42)
  3. c In combined tests with mammography and Trx1 level, it was regarded as positive when the test results showed the BI-RADS category over 4 or the Trx1 level was higher than the cut-off value (11.4 ng/ml). Similarly, it was regarded as negative when either result was in BI-RADS categories 1-3 or lower Trx1 level than the cut-off value
  4. d It is impossible to get 100% specificity in the real world. However, the test set in the present study showed mathematically perfect results due to the relatively small number of women without cancer, which indicates the potential of the combined tests